In addition, other peptide cancer vaccines are developed for prostate cancer, inter alia cancer-associated membrane carbohydrates such as mucin 1 (MUC1), ganglioside (GM2), Thompson-Friedenreich antigen, and globo H. More specifically, GVAX, DCVAC/PCa, a multi-epitope peptide vaccine, sipuleucel-T, and PROSTVAC strategies have been investigated in phase III trials. The gene discussed is MUC1; the disease is posterior cortical atrophy.